Full-Time
Primary Market Research Associate
TechAtlas Research
Posted on 8/20/2025
RA Capital Management
Invests in healthcare, life sciences.
No salary listed
No H1B Sponsorship
Boston, MA, USA
Hybrid
Must be based in Boston with ability to work out of our downtown Boston office on a hybrid schedule.
 Biology & Biotech (4) |
|---|
| , , , |
- Prior experience in life sciences is required (e.g. college degree in life sciences and/or experience in a life science / pharmaceutical consulting)
- 2–3 years of experience in primary market research or life sciences consulting; direct experience with survey design and execution is required.
- Demonstrated ability to translate scientific and business questions into structured PMR studies.
- Strong Excel skills (pivot tables, data analysis, modeling); experience with Power BI or Tableau is a plus.
- Excellent critical thinking skills and the ability to surface actionable insights from noisy or incomplete data.
- Clear and concise communication skills, including writing, presenting, and data storytelling.
- Must be based in Boston with ability to work out of our downtown Boston office on a hybrid schedule.
- Must be authorized to work in the United States without sponsorship.
- Design and execute primary market research (PMR) surveys, including questionnaire development, logic testing, sampling strategy, data quality control, and validation.
- Collaborate closely with investment associates and analysts to frame research objectives, align on survey approach, and ensure the right business questions are answered.
- Conduct and synthesize primary and secondary market research to evaluate market trends, competitive landscapes, unmet needs, and investment opportunities.
- Analyze data from surveys, healthcare claims, and third-party industry sources to generate insights on market size, adoption patterns, pricing dynamics, and stakeholder behavior.
- Develop compelling visualizations and deliverables that clearly communicate insights to support investment decision-making.
- Organize, clean, and model complex datasets using Excel and other analytical tools.
- Continuously improve our PMR capabilities by introducing and trialing innovative research methodologies, tools, and automation strategies.
- Bachelor’s degree in life sciences (Biology, Chemistry, etc.) preferred.
- Familiarity with healthcare data sources (e.g., claims, registries, syndicated reports) is desirable.
- Experience with Qualtrics, SurveyMonkey, or similar survey platforms is a plus.
- Familiarity with SQL, Python, or R is advantageous but not required.
RA Capital Management channels capital and expertise into healthcare, life sciences, and planetary health companies across growth stages. It funds ventures from private seed rounds to public follow-ons and uses evidence-based investing to guide decisions. Its TechAtlas research engine and Raven incubator provide internal data and a collaborative platform for entrepreneurs to develop and commercialize ideas. The firm aims to grow value for its portfolio and stakeholders by supporting companies that advance health outcomes, managing over $10 billion in assets.
Company Size
N/A
Company Stage
N/A
Total Funding
$37.7B
Headquarters
Boston, Massachusetts
Founded
2001
Simplify's Take
What believers are saying
- ARS Pharma $250M facility demonstrates market demand for innovative financing beyond equity.
- Portfolio company Adcendo's $75M Series C validates oncology investment thesis execution.
- Rhythm Pharmaceuticals position increase signals confidence in underserved rare disease therapeutics market.
What critics are saying
- ARS Pharma neffy commercialization fails against entrenched EpiPen competition, impairing $250M loan.
- Portfolio value collapsed 40% from $16.4B to $9.76B, triggering investor redemptions.
- Concentrated biotech holdings face clinical trial failures cratering portfolio valuations within months.
What makes RA Capital Management unique
- Structured Capital strategy provides flexible equity, debt, royalty, and hybrid financing solutions.
- Multi-stage investment approach spans venture, growth, and public market healthcare companies.
- Expanding climate and sustainability technology portfolio complements core healthcare life sciences focus.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Flexible Work Hours
Professional Development Budget
Company News
Novo Holdings joins $165 million crossover financing for Windward Bio to advance pipeline of long-acting immunology therapies with best-in-disease potential. * Led by OrbiMed, with participation from RA Capital Management, Janus Henderson Investors, Sanofi Ventures, and existing investors, including Novo Holdings * Proceeds will advance lead candidate WIN378 into Phase 3 and WIN027 into respiratory and dermatology studies by Q4 2026 * WIN378 has the potential to be the first-to-market ultra long-acting anti-TSLP antibody for asthma and COPD * WIN027 is a long-acting bispecific targeting TSLP and IL-13 with best-in-disease efficacy potential Windward Bio, a private, clinical-stage biotechnology company committed to improving outcomes for people living with serious immunological diseases, today announced an upsized $165 million crossover financing led by OrbiMed, with participation from existing Series A investors including Novo Holdings, Blue Owl Healthcare Opportunities, SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal bioVenture Partners. The financing also included new investors RA Capital Management, Janus Henderson Investors, and Sanofi Ventures. Proceeds will significantly extend the company's cash runway and enable multiple clinical readouts in the next 12 months. Since launching in January 2025, Windward Bio has in-licensed 2 clinical-stage assets, raised $365 million, and rapidly advanced both programmes[RW1] in the clinic. WIN378, the lead programme, is a next-generation, fully human monoclonal antibody that potently binds to the thymic stromal lymphopoietin (TSLP) ligand. This well-validated cytokine plays a key role in the development and progression of a wide array of immunological diseases. WIN378 has the potential to be the first-to-market, ultra long-acting anti-TSLP antibody with twice-yearly dosing. The financing will accelerate the development of WIN378, which is currently being studied in the Phase 2/3 POLARIS programme in asthma. The Phase 2 dose-ranging component of POLARIS is fully recruited, with initial data expected in the second half of 2026. The first Phase 3 study of WIN378 is expected to begin in the fourth quarter of 2026. The Phase 2 SIRIUS study in chronic obstructive pulmonary disease (COPD) is anticipated to start in the second quarter of 2026. WIN027, the second programme, is a highly potent, long-acting bispecific antibody targeting both TSLP and interleukin-13 (IL-13) - two well-validated and synergistic drivers of inflammation in severe asthma, COPD, and atopic dermatitis. WIN027 is currently in a Phase 1 study with data readout expected by the end of 2026. The financing will support multiple proof-of-concept studies across respiratory and dermatology indications starting in in the fourth quarter of 2026. "We are excited to expand our shareholder base of top-tier investors to include RA Capital, Janus Henderson, and Sanofi Ventures" said Luca Santarelli, MD, Founder, Chief Executive Officer, and Board Chair of Windward Bio. "This financing further strengthens our balance sheet and allows us to further advance our programmes of next-generation therapies for patients living with serious respiratory and dermatological diseases." Naveed Siddiqi, Senior Partner, Venture Investments, Novo Holdings, said: "Spearheaded by a highly experienced clinical and commercial leadership consisting of serial entrepreneurs, Windward Bio has made rapid progress since it launched in 2025, including bringing in a second clinical stage asset, WIN027. There is much more to be done towards improving dosing frequency and outcomes for the benefit of patients suffering from serious and chronic immunological conditions, and as a significant shareholder, we are pleased to support Windward Bio as it advances its innovative and developing pipeline into late-stage trials." About WIN378 WIN378 is a next-generation, fully human monoclonal antibody that potently inhibits the TSLP ligand. This clinically validated target plays a key role in the development and progression of a wide array of immunological diseases, including asthma and COPD. WIN378 has been engineered to achieve half-life extension (HLE) and to have a silenced effector function. It has been studied in a Phase 1 trial, which confirmed an extended half-life suitable for twice-yearly dosing, demonstrated a low rate of antidrug antibodies, and was safe and well tolerated up to the highest dose tested. WIN378 is administered subcutaneously. Windward Bio licensed the global rights (excluding Greater China and several Southeast and West Asian countries) for WIN378 from Kelun Biotech (also known as SKB378) and Harbour BioMed (also known as HBM9378). WIN378 is currently being evaluated in the POLARIS Phase 2/3 asthma study with initial readouts expected in the second half of 2026. A Phase 2 study in COPD is anticipated to begin in the second quarter of 2026. About WIN027 WIN027 is a potential best-in-class, humanised bispecific monoclonal antibody with subpicomolar affinity for TSLP and IL-13, well-validated targets in immunological conditions. It has been engineered to achieve an extended half-life and enable less frequent dosing. Through this dual, long-acting inhibition, WIN027 is designed to set a new standard of efficacy in conditions such as asthma, COPD, and atopic dermatitis, potentially delivering deeper and more durable disease control than existing biologics. WIN027 is currently in Phase 1. Windward Bio licensed the global rights (excluding Greater China) for WIN027 from Qyuns Therapeutics (also known as QX027N). About Windward Bio Windward Bio is a clinical-stage biotechnology company with deep discovery, development, and commercialization expertise committed to transforming the treatment of people living with serious immunological conditions. Its lead programme is WIN378, a potential best-in-disease, ultra long-acting anti-TSLP monoclonal antibody currently in a Phase 2/3 trial for asthma. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bispecific with broad therapeutic potential across immunological diseases, which is currently in Phase 1. The company is building a discovery pipeline of long-acting bispecific antibodies, targeting validated biology in respiratory and dermatological conditions. Media Enquiries Marie-Louise Jersin, Senior Communications Lead, [email protected]
Adcendo, a Copenhagen-based biotech company developing antibody-drug conjugates for cancer treatment, has raised $75 million in an oversubscribed Series C round led by Jeito Capital. Vida Ventures, BPI France and EIFO joined as new investors, alongside existing backers including TCGX, RA Capital Management, TPG and Novo Holdings. The funding will support clinical milestones for Adcendo's pipeline, including the ADCE-T02 Phase I study in multiple tumour types, the ADCE-D01 study in soft tissue sarcoma and the ADCE-B05 study in squamous cell carcinomas. The company is advancing three antibody-drug conjugates targeting cancers with high unmet medical needs. Ksenija Pavletic from Jeito Capital and Rajul Jain from Vida Ventures will join Adcendo's board of directors.
Incyclix Bio has raised an additional $5 million in its Series B financing round from Hatteras, bringing new support to advance its clinical trial of INX-315. The novel CDK2 inhibitor targets patients with CDK4/6 inhibitor-resistant ER+/HER2- breast cancer or CCNE1-amplified solid tumours. The funding will support clinical development of INX-315 for treating advanced and metastatic breast and ovarian cancer. Hatteras joins existing Series B investors including Boxer Capital, RA Capital Management, Eshelman Ventures, Eli Lilly and Company, Pharmacosmos and Cape Fear BioCapital. The Phase 1/2 open-label dose-escalation and expansion trial of INX-315 is currently ongoing. Kseniya Simpson and Christy have joined Incyclix Bio's board following the investment.
Neurocrine bids $2.9B for Soleno with Vykat in PWS. April 6, 2026 Neurocrine Biosciences Inc. is making a play to take over Soleno Therapeutics Inc. for $53 per share in cash, which works out to an equity value of $2.9 billion. If it goes through, the move will add Vykat XR (diazoxide choline), a first-in-class therapy to treat hyperphagia, the defining feature of Prader-Willi syndrome, to San Diego-based Neurocrine's hopper. Since its U.S. FDA clearance and the launch in the second quarter of last year, Vykat has generated $190 million in 2025 revenue, including $92 million for Soleno, of Redwood City, Calif., in the fourth quarter alone. Shares of Soleno (NASDAQ:SLNO) were trading at $52.20, up $12.71, or 32%. Neurocrine's stock (NASDAQ:NBIX) was selling for $129.38, down $2.22. Sector tariff now more than a threat - for some rx companies. After nearly a year of threats and promises of a global biopharma tariff of 25% to 500%, U.S. President Donald Trump delivered it late last week. In the name of national security, he imposed a 100% sector tariff on prescription drugs and their associated ingredients beginning in about four months for large manufacturers and six months for smaller companies. However, depending on the drug, where it's made and whether a manufacturer has reached onshoring and pricing agreements with the Department of Health and Human Services, the actual tariff could be as low as 0%. Regardless, the timing could hardly be worse. Stipple launches with $100M for novel oncology targets. Stipple Bio Inc. raised $100 million in a series A financing co-led by RA Capital, a16z Bio+Health and Nextech Invest. The company was founded by Aaron Ring at Fred Hutchinson Cancer Center and Aashish Manglik at University of California, San Francisco, to identify novel epitopes expressed on tumor cells with limited expression on healthy tissue. Rather than focusing on targets that are over-expressed, Stipple's Pointillist platform looks for post-translational modifications, protein conformation changes or mis-location of proteins that lead to epitopes that are specific to cancer cells. The Cambridge, Mass.-based company expects to have its lead drug, STP-100, an antibody-drug conjugate that binds an undisclosed target, in the clinic in early 2027. Circuit split forming over state 340B laws. Do state laws requiring drug companies to give steep 340B drug discounts to an unlimited number of contract pharmacies, with no claims data required, interfere with a longstanding contract between the U.S. Congress and biopharma? Or do such laws merely flex states' authority over pharmacy practices such as delivery? Those questions are at the heart of a new circuit split, which could eventually take the dispute to the Supreme Court. One-carbon has new approach to starving tumors of nucleotides. Swedish startup One-carbon Therapeutics AB is going after solid tumors with an approach that looks similar to synthetic lethals to some people, and to chemotherapy to others. But One-carbon CEO Ana Slipicevic said that TH-9619, the company's first-in-class inhibitor of the enzyme MTHFD1/2, is neither of those things. Slipicevic told BioWorld that there are some similarities to the synthetic lethal approach, in that TH-9619 targets a pathway that cancer cells are uniquely vulnerable to, and works in part by preventing them from repairing their DNA. Another similarity is that like PARP inhibitors, which are the icon of synthetic lethal targeting, MTHFD1/2 inhibition originated in the lab of Thomas Helleday. "We are a spin-off from Karolinska [Institute], and [MTHFD inhibition] went through a lot of early work in academia before we took over," Slipicevic said. Biopharma financings nearly double vs. 2025 to $25.1B. Total biopharma financings reached $25.14 billion in the first quarter (Q1) of 2026, nearly doubling the $13.12 billion in Q1 2025. The early 2026 total comes in above the $13.19 billion recorded in 2023 and $13.66 billion in 2022, though it remains below the $38.27 billion during the same period in 2021 and $47.25 billion in 2024. Holiday notice. BioWorld's offices were closed in observance of Good Friday. No issue was published April 3. Also in the news. Adagene, Akebia, Alto, Arcellx, Arch, Astrazeneca, Axsome, Beam, Boston Scientific, BSM, Celldex, Clarametyx, Cocrystal, Context, Coya, Curve, Eli Lilly, Ellipsys Medical, Entera, Fore, Gilead, Harmony, Hoth, Immunovant, Incyte, Inovio, Lipocine, Lupin, MDIC, Merck, Neutrolis, Novo Nordisk, Oncotelic, Orionis, Pangia, Pavmed, Puretech, Seaport, Shionogi, Soligenix, Stairmed, Tanabe, Techforce Robotics, Telix, Tenpoint, Ultragenyx, Valencia, Vascarta, Visufarma, Zeto To read more on related topics, click on one of the words below.
Stipple Bio emerges from stealth with $100M Series A to advance STP-100 ADC and Pointillist epitope platform.